Saturday 17 October 2026
Export AVBP’s income statement to Excel — free account
ArriVent BioPharma, Inc.
AVBP Healthcare Biotechnology
In the quarter to June 2026, EPS fell 16.7% and free cash flow fell 51.5%, each against the same quarter a year earlier.
16.66
0.13
−0.77%
Follow AVBP
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 14.35 | 15.47 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 36.37 | 29.71 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 40 | 40 | 52 | 77 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | (52) | (37) | (69) | (80) | (166) | |||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | (52) | (37) | (69) | (80) | (166) | |||||
| Depreciation | — | — | — | — | — | — | — | — | — | (3) | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | (72.58) | (28.90) | (32.38) | (2.56) | (4.32) | |||||
| Cash flow | — | — | — | — | — | (17.70) | (34.17) | (26.08) | (2.23) | (4.18) | |||||
| Capex | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | — | (17.70) | (34.17) | (26.08) | (2.23) | (4.18) | |||||
| Book value | — | — | — | — | — | 57.98 | 136.62 | 70.67 | 8.19 | 7.99 | |||||
| Shares, m | — | — | — | — | — | 1 | 1 | 2 | 31 | 38 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (13) | (44) | (56) | (70) | (161) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | — | (13) | (44) | (56) | (70) | (161) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 41 | 174 | 148 | 210 | 307 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | (37) | (163) | (150) | (219) | (313) | |||||
| Shareholders’ equity | — | — | — | — | — | 41 | 174 | 151 | 258 | 307 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | (32.68) | (40.08) | (36.75) | (54.70) | ||||
| ROIC | — | — | — | — | — | (818.42) | (207.99) | (5,134.22) | (151.95) | 0.00 | |||||
| ROE | — | — | — | — | — | 0.00 | 55.19 | 58.19 | (154.10) | (58.88) | |||||
Negative figures in brackets.
Charts ten years each
ArriVent BioPharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GLUE Monte Rosa Therapeutics, Inc. | $863.4M | — (loss-making) | — (loss-making) | −61.33% (below 0%: shrinking) | n/m | −34.11% (below 0%: shrinking) | 100.00% | (547.84%) | Compare |
| KURA Kura Oncology, Inc. | $862.9M | — (loss-making) | — (loss-making) | +36.54% (above 0%: growing) | n/m | −109.05% (below 0%: shrinking) | 98.84% | (349.77%) | Compare |
| ALMS Alumis Inc. | $842.4M | — (loss-making) | — (loss-making) | −37.66% (below 0%: shrinking) | n/m | +23.59% (above 0%: growing) | 100.00% | (8,956.38%) | Compare |
| VSTM Verastem, Inc. | $835.9M | — (loss-making) | — (loss-making) | +1,775.43% (above 0%: growing) | n/m | −34.43% (below 0%: shrinking) | 89.92% | (81.62%) | Compare |
| CRVS Corvus Pharmaceuticals, Inc. | $828.6M | — (loss-making) | — | — | n/m | −171.31% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AVBP ArriVent BioPharma, Inc. | $827.9M | — (loss-making) | — | — | n/m | −51.51% (below 0%: shrinking) | — | 0.00% | |
| ARDX Ardelyx, Inc. | $814.9M | — (loss-making) | — (loss-making) | +23.77% (above 0%: growing) | n/m | +75.33% (above 0%: growing) | 95.24% | (10.28%) | Compare |
| HELP Cybin Inc. | $807.3M | — (loss-making) | — (loss-making) | — | n/m | −25.60% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| DNA Ginkgo Bioworks Holdings, Inc. | $791.9M | — (loss-making) | — (loss-making) | −48.49% (below 0%: shrinking) | n/m | −16.38% (below 0%: shrinking) | 91.47% | (290.47%) | Compare |
| Median of peers | $832.2M | — | — | −6.94% | — | −29.85% | 93.36% | (186.05%) |
ArriVent BioPharma, Inc. (AVBP) key facts
- ArriVent BioPharma, Inc. (AVBP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, AVBP traded at $16.66, a market capitalization of $827.9 million.
- Return on equity was −58.9% and debt-to-equity 0.00.